Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
GSK
(NYSE:GSK)
Intraday
$41.24
0.65
[1.60%]
After-Hours
$41.24
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$41.24
0.65
[1.60%]
At close: Apr 23
$41.24
0
[0.00%]
After Hours: 4:26PM EDT
Get Report
Watch
Q1 2024 Earnings in 7 days from now on Wed May 1st, before the market open
Conference call scheduled in 7 days at 7:00 AM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for GSK Stock (NYSE:GSK)
GSK Stock (NYSE: GSK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 23, 2024
As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
Benzinga Newsdesk
-
14 hours ago
Monday, April 22, 2024
Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits
Benzinga Newsdesk
-
1 day ago
Friday, April 19, 2024
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Vandana Singh
-
4 days ago
Thursday, April 18, 2024
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Vandana Singh
-
5 days ago
Wednesday, April 17, 2024
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
Vandana Singh
-
6 days ago
GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea
Benzinga Newsdesk
-
6 days ago
GSK Says New Long-Term Data Show Shingrix Continues To Provide Protection Against Shingles In Adults Aged 50 And Over For More Than A Decade
Benzinga Newsdesk
-
6 days ago
Thursday, April 11, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Avi Kapoor
-
Apr 11, 2024, 7:48AM
Thursday, April 04, 2024
CureVac, GSK Partner Release Data On Influenza Vaccine Study
Vandana Singh
-
Apr 4, 2024, 12:18PM
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Vandana Singh
-
Apr 4, 2024, 9:16AM
CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Benzinga Newsdesk
-
Apr 4, 2024, 7:07AM
Tuesday, March 26, 2024
Peering Into GSK's Recent Short Interest
Benzinga Insights
-
Mar 26, 2024, 2:00PM
Thursday, March 21, 2024
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Vandana Singh
-
Mar 21, 2024, 7:17AM
Monday, March 18, 2024
U.S. CDC Issues Health Alert Network Health Advisory On Increase In Global And Domestic Measles Cases And Outbreaks; Says Ensure Children In The United States And Those Traveling Internationally 6 Months And Older Are Current On MMR Vaccination
Benzinga Newsdesk
-
Mar 18, 2024, 1:54PM
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
Vandana Singh
-
Mar 18, 2024, 12:17PM
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Vandana Singh
-
Mar 18, 2024, 12:08PM
Reported Saturday, GSK Announced RUBY Phase III Data Show Potential For Jemperli (Dostarlimab-Gxly) Combinations In More Patients With Primary Advanced Or Recurrent Endometrial Cancer
Benzinga Newsdesk
-
Mar 18, 2024, 2:35AM
Monday, March 11, 2024
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Piero Cingari
-
Mar 11, 2024, 10:38AM
Thursday, March 07, 2024
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
Vandana Singh
-
Mar 7, 2024, 12:18PM
GSK shares are trading higher after the company announced results from its DREAMM-9 phase III trial of Blenrep in combination with pomalidomide plus dexamethasone verses a standard of care as a second line and later treatment for relapsed or refractory multiple myeloma.
Benzinga Newsdesk
-
Mar 7, 2024, 12:06PM
GSK's Headline Results From Interim Analysis Of DREAMM-8 Phase 3 Head-To-Head Trial Of Blenrep Plus Pomalidomide Plus Dexamethasone, Versus Standard Of Care As Second Line Treatment For Relapsed/Refractory Multiple Myeloma Show Trial Met Primary Endpoint
Benzinga Newsdesk
-
Mar 7, 2024, 6:33AM
Wednesday, March 06, 2024
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Vandana Singh
-
Mar 6, 2024, 5:00PM
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Mar 6, 2024, 12:35PM
GSK Plc - ViiV Lai Vs Oral Soc Data In Adherence-Challenged; ViiV Healthcare Announces Interim Data At CROI Indicating Superior Efficacy Of Long-Acting Injectable HIV Treatment Cabenuva; Cabenuva Demonstrated Superior Efficacy In Maintaining Viral Load Suppression Vs Daily Oral Therapy; Latitude Study Rate Of Adverse Events Was Similar In Both Arms
Benzinga Newsdesk
-
Mar 6, 2024, 11:04AM
Tuesday, March 05, 2024
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
Vandana Singh
-
Mar 5, 2024, 12:57PM
Monday, March 04, 2024
ViiV Healthcare Presents Phase I Clinical Trial Findings Of A Cabotegravir Long-Acting Injectable Investigational Formulation Allowing At Least 4-Months Between Doses
Benzinga Newsdesk
-
Mar 4, 2024, 1:52PM
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
Vandana Singh
-
Mar 4, 2024, 11:39AM
Guggenheim Upgrades GSK to Buy
Benzinga Newsdesk
-
Mar 4, 2024, 5:53AM
Thursday, February 29, 2024
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
Vandana Singh
-
Feb 29, 2024, 12:45PM
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month
Vandana Singh
-
Feb 29, 2024, 9:21AM
Gsk Has Reached A Confidential Settlement With Boyd/Steenvoord, Resolving The Case Filed In California State Court, Related To Zantac (Ranitidine) The Case Was Set To Begin Trial On 2 April 2024
Benzinga Newsdesk
-
Feb 29, 2024, 5:34AM
Wednesday, February 28, 2024
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Stjepan Kalinic
-
Feb 28, 2024, 2:43PM
Monday, February 26, 2024
GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection
Vandana Singh
-
Feb 26, 2024, 9:40AM
GSK's EAGLE-1 Phase 3 Trial Met Its Primary Efficacy Endpoint Of Non-inferiority Comparing Gepotidacin With Intramuscular Ceftriaxone Plus Oral Azithromycin Combination Therapy For Uncomplicated Urogenital Gonorrhoea
Benzinga Newsdesk
-
Feb 26, 2024, 5:14AM
Wednesday, February 21, 2024
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Surbhi Jain
-
Feb 21, 2024, 3:02PM
Wednesday, February 14, 2024
GSK Exercises Option To License Elsie Biotechnologies' Discovery Platform To Find And Develop Novel Oligonucleotides
Benzinga Newsdesk
-
Feb 14, 2024, 8:15AM
Monday, February 12, 2024
Looking Into GSK's Recent Short Interest
Benzinga Insights
-
Feb 12, 2024, 2:45PM
Friday, February 09, 2024
Why Is Moderna Stock Trading Lower Today?
Vandana Singh
-
Feb 9, 2024, 12:03PM
Thursday, February 08, 2024
Alector And GSK Have Announced To Dose The First Patient In PROGRESS-AD Phase 2 Trial Of AL101/GSK4527226 In Patients With Early Alzheimer's Disease
Benzinga Newsdesk
-
Feb 8, 2024, 7:09AM
Wednesday, February 07, 2024
The FDA Has Granted Breakthrough Therapy Designation To Alector/GSK's Latozinemab, An Investigational Human Monoclonal Antibody Designed To Block Sortilin To Elevate Progranulin Levels For To Treat Frontotemporal Dementia With A Progranulin Gene Mutation
Benzinga Newsdesk
-
Feb 7, 2024, 7:12AM
Tuesday, February 06, 2024
Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?'
Avi Kapoor
-
Feb 6, 2024, 10:56AM
GSK Announced DREAMM-7 Phase III Trial Shows Blenrep Combination Nearly Tripled Median Progression-free Survival Versus Standard Of Care Combination In Patients With Relapsed/refractory Multiple Myeloma
Charles Gross
-
Feb 6, 2024, 6:55AM
The Center For Drug Evaluation Of The China National Medical Products Administration Has Accepted For Review The Regulatory Application Of GSK's Shingrix (Recombinant Zoster Vaccine) For The Prevention Of Shingles (Herpes Zoster) In Adults
Benzinga Newsdesk
-
Feb 6, 2024, 3:43AM
The FDA Has Accepted Under Priority Review GSK's Application To Extend The Indication Of Its Adjuvanted Respiratory Syncytial Virus Vaccine To Adults Aged 50-59 Who Are At Increased Risk For Respiratory Syncytial Virus Disease
Benzinga Newsdesk
-
Feb 6, 2024, 3:41AM
Friday, February 02, 2024
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
Vandana Singh
-
Feb 2, 2024, 2:01PM
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
Vandana Singh
-
Feb 2, 2024, 12:41PM
Thursday, February 01, 2024
What's Going On With GSK Stock Today?
Vandana Singh
-
Feb 1, 2024, 2:19PM
GSK Today Announced A Confidential Settlement With David Browne In Zantac Litigation Case
Charles Gross
-
Feb 1, 2024, 6:54AM
Wednesday, January 31, 2024
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine
Vandana Singh
-
Jan 31, 2024, 8:50AM
GSK shares are trading higher after the company reported mixed Q4 financial results and issued guidance.
Benzinga Newsdesk
-
Jan 31, 2024, 8:40AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch